Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021)

Ginkgo Bioworks Holdings (DNA) reported Preferred Stock Liabilities of $1.5 billion for Q2 2021, down 6.79% quarter-over-quarter from $1.6 billion in Q1 2021.

Ginkgo Bioworks Holdings (DNA) Preferred Stock Liabilities (2021) Analysis & Trends

Ginkgo Bioworks Holdings has reported Preferred Stock Liabilities for 1 years, with the latest figure at $1.5 billion in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Ginkgo Bioworks Holdings 546.79 Mn 546.79 Mn 16.38 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2021 1.47 Bn
Mar 31, 2021 1.57 Bn